DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

CRL·Charles River Laboratories International, Inc.

$.
+. (+.%)
Pre-Market
High
$229.75
Open
$229.75
Market Cap
11.29B
52W High
$237.86
Low
$229.75
P. Close
$229.75
P/E
-
52W Low
$144.26
Fwd P/E
18.63
DailyIQ Est.
$231.29
Technical Score (1D)
82
BUY
News Sentiment
70
BULLISH
Charles River Laboratories announced a new partnership with Arovella Therapeutics to supply GMP‑compliant next‑generation sequencing (NGS) services for the company’s invariant natural killer T (iNKT) cell therapy platform, a development that came just hours ago. The collaboration follows FDA approval of NGS for viral safety testing in Arovella’s IND application, confirming the technology’s regulatory acceptance and easing the path to clinical manufacturing. By adding this service to its portfolio, CRL expands its footprint in the rapidly growing cell‑therapy supply chain, positioning itself as a mandatory partner for advanced biotherapeutics. The deal not only boosts CRL’s revenue prospects from a high‑margin service but also signals increasing demand for GMP‑NGS in the biotech R&D sector, which could drive further client acquisition. In the next 1–10 trading days, investors should watch for any subsequent announcements of additional clients or expanded service offerings that could reinforce CRL’s market leadership. The partnership also underscores the broader trend of regulatory bodies embracing advanced sequencing for safety testing, potentially accelerating the commercialization of cell therapies. Analysts will likely monitor CRL’s earnings guidance for any upward revisions tied to this new revenue stream. Finally, keep an eye on Arovella’s clinical milestones, as progress there could amplify demand for CRL’s services and validate the partnership’s strategic fit.
Earnings Summary
Charles River Laboratories International (CRL) is a global provider of essential services for the pharmaceutical and biotechnology industries, operating through Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments that support the entire drug‑development lifecycle; it functions within the healthcare diagnostics and research sector. In the most recent quarters, CRL’s Q4 2025 revenue of $994.23 million was slightly below the $998.10 million estimate, while EPS of $2.39 beat the $2.56 estimate; Q1 2026 revenue of $995.83 million exceeded the $987.26 million estimate and EPS of $2.06 surpassed the $1.94 estimate, indicating a modest revenue rebound and continued earnings strength, with EPS beating estimates in all six quarters reported. Historically, year‑over‑year revenue has hovered near $1 billion, with a slight dip in Q4 2025 compared to Q4 2024 but a rebound in Q1 2026, while EPS has consistently outperformed analyst expectations, underscoring a pattern of earnings resilience despite flat revenue growth. Recent analyst commentary—highlighted by Morgan Stanley’s price‑target lift to $260, Evercore’s upgrade to $260, and Argus Analytics’ $250 target—emphasizes a bullish consensus on CRL’s pipeline and contract‑research expansion, suggesting that market sentiment is aligned with the company’s earnings trajectory; these upgrades also point to heightened sensitivity to regulatory developments and currency exposure. Investors should watch for the upcoming earnings guidance for any updates on the contract‑research pipeline, currency‑hedging strategies, and potential new product launches, as well as any regulatory announcements that could influence demand for CRL’s services, with key focus on how guidance aligns with the recent upward analyst revisions and the company’s demonstrated EPS‑beat consistency.

EPS

EstBeatMiss
$1.77$2.15$2.53$2.91$3.30Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.73 - -
Q1'26$1.94$2.06+6.0%
Q4'25$2.56$2.39-6.6%
Q3'25$2.34$2.43+3.9%
Q2'25$2.55$3.12+22.4%
Q1'25$2.07$2.34+12.8%

Revenue

EstBeatMiss
$976M$992M$1.0B$1.0B$1.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$983M - -
Q1'26$987M$996M+0.9%
Q4'25$998M$994M-0.4%
Q3'25 - $1.0B -
Q2'25 - $1.0B -
Q1'25 - $984M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CRL Stock Snapshot

CRL is currently trading at $229.75, giving Charles River Laboratories International, Inc. a market cap of 11.29B. Today's range spans $229.75–$229.75, with shares opening at $229.75 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 70/100.

Over the past year CRL has traded between $144.26 and $237.86 - the current price is +59.3% off the 52-week low and -3.4% from the high. 25 analysts cover the stock with a Buy consensus and a mean 12-month target of $220.67 (range $135.00–$265.00), implying downside of -4.0%.

In the Healthcare peer group, Charles River Laboratories International, Inc. (CRL) stands out for a BUY signal backed by aligned sentiment - score 82/100, sentiment bullish at 70/100, price $229.75 (near 52-week highs). With 11.29B in market cap, this is large enough to feature on institutional watch lists but small enough to re-rate meaningfully on a positive earnings surprise. The 52-week span of $144.26–$237.86 shows the stock has already proven it can make significant moves.

What makes CRL's BUY setup (82/100) particularly actionable at 11.29B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $229.75 (near 52-week highs in $144.26–$237.86), with sentiment running bullish at 70/100, the setup rewards conviction-sized positioning more than it does speculative small bets.